These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 29433982)

  • 1. Bimolecular Fluorescence Complementation of Alpha-synuclein Demonstrates its Oligomerization with Dopaminergic Phenotype in Mice.
    Cai W; Feng D; Schwarzschild MA; McLean PJ; Chen X
    EBioMedicine; 2018 Mar; 29():13-22. PubMed ID: 29433982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the Effect of β-Wrapin AS69 in a Mouse Model Based on Alpha-Synuclein Overexpression.
    Höfs L; Geißler-Lösch D; Wunderlich KM; Szegö EM; Van den Haute C; Baekelandt V; Hoyer W; Falkenburger BH
    Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.
    Oliveras-Salvá M; Van der Perren A; Casadei N; Stroobants S; Nuber S; D'Hooge R; Van den Haute C; Baekelandt V
    Mol Neurodegener; 2013 Nov; 8():44. PubMed ID: 24267638
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
    Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
    Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
    Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
    Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MHC class II transactivator modulates seeded alpha-synuclein pathology and dopaminergic neurodegeneration in an in vivo rat model of Parkinson's disease.
    Jimenez-Ferrer I; Bäckström F; Dueñas-Rey A; Jewett M; Boza-Serrano A; Luk KC; Deierborg T; Swanberg M
    Brain Behav Immun; 2021 Jan; 91():369-382. PubMed ID: 33223048
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Administration of AAV-Alpha Synuclein NAC Antibody Improves Locomotor Behavior in Rats Overexpressing Alpha Synuclein.
    Chen YH; Wu KJ; Hsieh W; Harvey BK; Hoffer BJ; Wang Y; Yu SJ
    Genes (Basel); 2021 Jun; 12(6):. PubMed ID: 34205689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 14-3-3 mitigates alpha-synuclein aggregation and toxicity in the in vivo preformed fibril model.
    Underwood R; Gannon M; Pathak A; Kapa N; Chandra S; Klop A; Yacoubian TA
    Acta Neuropathol Commun; 2021 Jan; 9(1):13. PubMed ID: 33413679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modeling Parkinson's Disease Neuropathology and Symptoms by Intranigral Inoculation of Preformed Human α-Synuclein Oligomers.
    Boi L; Pisanu A; Palmas MF; Fusco G; Carboni E; Casu MA; Satta V; Scherma M; Janda E; Mocci I; Mulas G; Ena A; Spiga S; Fadda P; De Simone A; Carta AR
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198335
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain.
    Delenclos M; Faroqi AH; Yue M; Kurti A; Castanedes-Casey M; Rousseau L; Phillips V; Dickson DW; Fryer JD; McLean PJ
    Acta Neuropathol Commun; 2017 Jun; 5(1):51. PubMed ID: 28645308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system.
    Kirik D; Rosenblad C; Burger C; Lundberg C; Johansen TE; Muzyczka N; Mandel RJ; Björklund A
    J Neurosci; 2002 Apr; 22(7):2780-91. PubMed ID: 11923443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease.
    Yasuda T; Nihira T; Ren YR; Cao XQ; Wada K; Setsuie R; Kabuta T; Wada K; Hattori N; Mizuno Y; Mochizuki H
    J Neurochem; 2009 Feb; 108(4):932-44. PubMed ID: 19141079
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progressive neurodegenerative and behavioural changes induced by AAV-mediated overexpression of α-synuclein in midbrain dopamine neurons.
    Decressac M; Mattsson B; Lundblad M; Weikop P; Björklund A
    Neurobiol Dis; 2012 Mar; 45(3):939-53. PubMed ID: 22182688
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal follow-up and characterization of a robust rat model for Parkinson's disease based on overexpression of alpha-synuclein with adeno-associated viral vectors.
    Van der Perren A; Toelen J; Casteels C; Macchi F; Van Rompuy AS; Sarre S; Casadei N; Nuber S; Himmelreich U; Osorio Garcia MI; Michotte Y; D'Hooge R; Bormans G; Van Laere K; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    Neurobiol Aging; 2015 Mar; 36(3):1543-58. PubMed ID: 25599874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Noninvasive bioluminescence imaging of α-synuclein oligomerization in mouse brain using split firefly luciferase reporters.
    Aelvoet SA; Ibrahimi A; Macchi F; Gijsbers R; Van den Haute C; Debyser Z; Baekelandt V
    J Neurosci; 2014 Dec; 34(49):16518-32. PubMed ID: 25471588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Depressive-like phenotype induced by AAV-mediated overexpression of human α-synuclein in midbrain dopaminergic neurons.
    Caudal D; Alvarsson A; Björklund A; Svenningsson P
    Exp Neurol; 2015 Nov; 273():243-52. PubMed ID: 26363495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rab1A over-expression prevents Golgi apparatus fragmentation and partially corrects motor deficits in an alpha-synuclein based rat model of Parkinson's disease.
    Coune PG; Bensadoun JC; Aebischer P; Schneider BL
    J Parkinsons Dis; 2011; 1(4):373-87. PubMed ID: 23939344
    [TBL] [Abstract][Full Text] [Related]  

  • 18. How can rAAV-α-synuclein and the fibril α-synuclein models advance our understanding of Parkinson's disease?
    Volpicelli-Daley LA; Kirik D; Stoyka LE; Standaert DG; Harms AS
    J Neurochem; 2016 Oct; 139 Suppl 1(Suppl 1):131-155. PubMed ID: 27018978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zonisamide attenuates α-synuclein neurotoxicity by an aggregation-independent mechanism in a rat model of familial Parkinson's disease.
    Arawaka S; Fukushima S; Sato H; Sasaki A; Koga K; Koyama S; Kato T
    PLoS One; 2014; 9(2):e89076. PubMed ID: 24586512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct detection of alpha synuclein oligomers in vivo.
    Dimant H; Kalia SK; Kalia LV; Zhu LN; Kibuuka L; Ebrahimi-Fakhari D; McFarland NR; Fan Z; Hyman BT; McLean PJ
    Acta Neuropathol Commun; 2013 May; 1():6. PubMed ID: 24252244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.